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Executive Summary  
 
 
For Intermittent Preventive Treatment of Malaria in Children (IPTc) to be accepted and sustainable as a 
malaria control strategy it must be affordable and cost effective as well as safe and acceptable. Thus, 
several of the IPTc studies have included an economic component. These studies range from randomised 
controlled trials to operational research studies.  In addition, modelling was used to supplement the 
information available from the trials and to provide predictions where the trials could not, for practical 
reasons, provide estimates. Both financial and economic costs associated with IPTc delivery have been 
investigated to help forecast how introducing the intervention may impact health budgets, and to help 
determine the cost effectiveness of IPTc compared to other malaria interventions.  
 
In this report we present the costs and cost-effective of IPTc using three different drug regimens and 
various delivery strategies.  Across all studies, the financial cost per IPTc course range from US$0.24 to 
US$3.44 and the economic cost per course from US$0.31 to US$3.44. These costs are within the range of 
the costs associated with delivering existing malaria control interventions.  The cost effectiveness of the 
intervention was comparable, but marginally higher than other prevention strategies, however 
possibilities exist for reducing the costs of IPTc by scaling up and by incorporating delivery of IPTc with the 
delivery of other interventions such as the distribution of Vitamin A or Community and Home 
Management  of Malaria.   Supervision, training and remuneration of CHWs and IPTc drug delivery have 
been identified as the main cost components and key determinants to the success of the delivery 
strategy.  There is scope for the costs associated with supervision and training to be reduced if IPTc is 
integrated into existing routine activities.  Alternatively, in settings where supervision and training of 
CHWs is weak, IPTc may offer an opportunity to strengthen both these important aspects of service 
delivery which will offer benefits beyond reducing malaria morbidity and mortality.    
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1. Introduction 
 
In addition to the devastating impact malaria can have on an individual’s health, it also impacts the 
economic wellbeing of households, communities and nations.  It is, therefore, incumbent on governments 
to supply and households to demand interventions that are known to successfully prevent and treat 
malaria.  When deciding which interventions to select (both at the government and the household level) 
decisions have to be made about where to allocate limited funds and how best to use the resources of the 
health system.  
 
Many issues are of critical concern when deciding where limited resources should be allocated.  Two 
important considerations are the costs of an intervention and its ‘value for money’.  Costs are important 
because, in a context of limited finances and changing government and international commitments, there 
needs to be an accurate forecast of how an intervention will impact the health budget. Economic 
evaluations help to determine the relative efficiency of different choices and provide an explicit indication 
of how competing strategies compare in terms of their ‘value for money’[1]. 
 
Recent trials have shown that Intermittent Preventive Treatment of Malaria in Children (IPTc) is a highly 
efficacious and effective intervention against uncomplicated and severe malaria [2]. Economic evaluations 
have been conducted alongside many of these studies to explore which drug combinations and delivery 
strategies are most cost effective. In this report, we summaries what has been published to date on the 
economics of IPTc and present for the first time the preliminary costing of a large scale IPTc delivery study 
in Senegal. We then compare the costs and cost effectiveness of IPTc to the costs and cost effectiveness 
of other malaria interventions.  Finally we discuss the key issues associated with the delivery of IPTc. 
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2. Review of economic aspects of IPTc studies to date 
 
For IPTc to be accepted and sustainable as a malaria control strategy it must be cost effective as well as  
safe and acceptable. Thus, several of the IPTc studies have included, or have an ongoing, economic 
component (Annex 1). These studies range from randomised controlled trials to operational research 
studies.  Both financial and economic costs1 associated with IPTc delivery have been or are being 
collected.  The cost implications of different drug regimens have been studied in Hohoe, Ghana both from 
the perspective of the clinical trial and when modeled to reflect district wide implementation[3].  The 
costs of different delivery strategies have been studied in Basse, The Gambia and in Jasikan, Ghana [4,5] 
and the cost of IPTc when organised by the district health services has been studied in Tivaouane, Senegal 
[6].  Modeling was undertaken to predict the impact and cost-effectiveness where, for practical reasons, 
trials cannot be carried out; for many different settings and implementation characteristics and to capture 
the effects of severe episodes and deaths.  The effects of different target age groups, seasonal or year-
round delivery, transmission intensity, seasonality, proportion of malaria fevers treated and drug 
characteristics have been simulated[7]. 
 
While it is straightforward calculating the costs of IPTc, it is a little more complicated to decide on the 
most relevant effects to use as the denominator of the cost effectiveness ratio2.  The effect that is 
measured as part of an economic evaluation is led by the clinical trial outcomes.  A number of possible 
outcome measures were identified in the various IPTc trials.  When possible an actual health gain was 
measured, i.e. cost per malaria case, death or DALY averted [3,4,7]. Where a health gain was not 
identified as part of the trial, the level of coverage was used as an intermediate measure [5,6]. As IPTc 
involves multiple doses and multiple courses, there are a number of potential outcome measures.  To 
date, the primary outcome measure used in the economic evaluations has been the cost per child 
adherent to ‘at least the first dose of each course’.  This measure was seen as a fair representation of the 
intended aim of the intervention.  There is an argument that a child who receives just the first dose of one 
course receives some protection and therefore the cost per course is a valid outcome measure. This 
applies particularly to IPTc regimens which employ sulphadoxine/pyrimethamine (SP) as, in areas where 
parasites remain sensitive to this antimalarial, a single dose will provide substantial protection and is 
                                                 
1 Evaluation of financial costs of resources required to set-up and run the innovation in terms of the actual 
expenditures incurred (the price paid for the resources).  Evaluation of economic costs captures the 
opportunity cost of all resources used to produce the innovation, whether or not they incur a financial 
cost. For example any donated or subsidised items used by the programme would need to be valued at 
market prices to estimate their economic cost.  
2  Cost effectiveness ration (CER)= (intervention costs –baseline costs)       
                                                          (intervention effects –baseline effects)      
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recommended for IPT in pregnant women and infants.  More discussion of this issue is provided in the 
section on the costings of the Senegal study (see below). Given the benefits of partial as well total 
adherence to IPTc, we show the unit costs of both in Table 1, i.e. ‘the cost per course’ and ‘cost per child 
adherent to at least the first dose of each course’ respectively.  Table 1 also shows the difference between 
the financial costs and economic costs of delivering IPTc.  While financial costs are important for planning 
budgets and indicating how much additional expenditure is needed, economist tend to focus on the 
economic costs of interventions as these show the full costs of all the resources used to deliver an 
intervention and allow more insightful comparisons between different interventions.  
 
To make comparisons across studies easier all costs are inflated and presented as their US$2010 
equivalent, unless otherwise stated[8]. Costs in this report may, therefore, vary slightly from those in the 
original publications.  
 
Table 1: Summary of Unit Cost of Delivering IPTc (US$ 2010) 
Study Site Description* 
(IPTc drugs/  
Delivery strategy) 
Number 
of 
courses 
Cost per  course Child adherent to ‘at 
least the first dose of 
each course’ 
Source 
   Financial Economic Financial Economic  
Hohoe, 
Ghana 
 
SP Bimonthly, CHW 
 
AQ&AS Monthly, CHW 
 
AQ&AS, Bimonthly, CHW 
 
3 
 
6 
 
3 
 0.75 
 
1.84 
 
1.14 
 
1.24 
 
2.31 
 
1.67 
4.25** 
(1.27) 
11.97 
(3.66) 
7.39 
(2.11) 
8.30  
(1.74) 
15.03 
(4.20) 
10.84 
(2.60) 
[3] 
Basse, 
Ghana 
SP&AQ, CHW 
 
SP&AQ, Outreach 
 
3 
 
3 
0.24 
 
0.39 
0.31 
 
0.47 
1.25 
 
3.03 
 
1.66 
 
3.53 
[4] 
Jasikan, 
Ghana 
SP&AQ, CHW  
 
SP&AQ OPD 
 
SP&AQ Outreach  
 
4 
 
4 
 
4 
2.41 
 
2.66 
 
2.81 
3.14 
 
3.32 
 
3.44 
3.39 
 
3.79 
 
4.54 
4.56 
 
4.83 
 
5.60 
[5] 
Tivaouane, 
Senegal 
SP&AQ, CHW 3 NA NA 2.65 3.73 [6] 
* See Annex 1 for more details of trial characteristics 
** Costs for Trial Conditions &  modeling district wide implementation in parenthesis 
CHW = Community Health Worker 
OPD = Outpatient Department 
NA= Not available 
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Figure 1 presents the costs broken down by cost categories by the economic per child who received at 
least the first dose of each course of IPTc for all the IPTc scenarios costed to date. Figure 2 presents these 
same costs by their percentage breakdowns.  
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Figure 1: Unit Cost (economic) per child receiving at least the first dose of IPTc each course 
 
 
NOTE: Hohoe Trial Setting: Cost per child receiving at least one course.  District Wide: Cost per child receiving at least one course assuming a district size of 33,000 children 
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Figure 2: Percentage Breakdown of IPTc Delivery Costs by Cost Category based on Figure 1 Unit Costs 
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Costs and Cost Effectiveness of Different IPTc Drug Regimens 
In the Hohoe study where up to 6 courses of treatment were given, the economic costs per child who 
received at least the first dose of each course of IPTc showed that, as expected, SP bimonthly, at US$8.30, 
was the cheapest to deliver, followed by AQ+AS bimonthly at US$10.84 and then by AQ+AS monthly at 
US$15.03[3].  Training, supervision and drug delivery (in terms of the personnel and transport needed to 
deliver the IPTc drugs to the CHW ahead of their monthly IPTc drug administration) accounted for 
approximately 20-30% each of total unit costs (Figure 2).  During the intervention period, AS + AQ monthly 
was the most cost effective drug regimen at US$68.64 (62.50, 75.71, CI 95%) per malaria case averted 
based on intervention costs only.  The costs of scaling up the intervention to 33,000 children, i.e. to 
district level, were modelled and under these conditions the cost per child enrolled fell considerably 
compared to costs under trial conditions as did the cost per malaria case averted.  Based on intervention 
costs only, IPTc using SP was US$28.59 (20.23, 42.65 CI 95%) per malaria case averted, US$22.60 (20.59, 
24.88 CI 95%) using AS+AQ monthly and US$60.37 (36.87, 115.02 CI 95%) using AS+AQ bimonthly.  This 
reduction in cost occurred because semi-fixed costs, such as training and drug delivery, benefited from 
economies of scale and fixed costs such as incentives to CHW and health facility staff were spread over a 
larger number of children per CHW or staff member delivering IPTc.  The economic evaluation of the 
Hohoe project did not take into account the potential savings that might have been achieved from 
preventing cases of severe malaria or death as these were not end-points of this trial.   
 
If IPTc were to be implemented routinely, additional benefits such as increased efficiency and lower costs 
of delivery could be achieved by integrating IPTc with other current successful health interventions aimed 
at the same populations; what economists term ‘economies of scope’. For example, if delivery was 
combined with other non-IPTc activities such as Vitamin A campaigns or home management of malaria 
(HMM) a fall in the costs of IPTc delivery would be likely together with a potential increase in IPTc access 
and coverage [9,10].   
 
The combination of SP+AQ used in several other studies of IPTc is likely to be more cost effective that the 
figures obtained during the study in  Hohoe because of the lower costs of SP than AS and similar or higher 
levels of protective efficacy. The Hohoe study was not powered to detect an impact on hospital 
admissions or mortality. However, subsequent larger studies of IPTc with SP+AQ conducted in Burkina 
Faso and Mali have shown a substantial reduction in hospital admissions with malaria in children who 
received IPTc [11,12]. Based on intervention costs alone IPTc may appear costly, however, once the 
savings to the health system and to households are included IPTc appears more favourable. The cost 
savings would have been more pronounced had there been more of an impact on severe episodes as has 
been observed in larger studies conducted in Burkina Faso and Mali. 
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Costs and Cost Effectiveness of Different IPTc Delivery Strategies 
In both the studies conducted in Basse, The Gambia, and in Jasikan, Ghana,  IPTc delivery by community 
health workers (CHWs) was found to be more effective (in terms of higher coverage) and less costly than 
delivery by those employed in the formal health system [4,5]. In Jasikan, the cost per child who took at 
least the first dose of all 3 IPTc courses was US$4.56 when the intervention was delivered by a CHW, 
US$4.83 when delivered via outreach and US$5.60 when delivered in an outpatient department, with 
supervision the largest cost component. In Basse, the economic costs of a fully adherent child who 
received all 3 doses of IPTc with SP+AQ were US$1.66 and US$3.53 when delivery was achieved via CHWs 
and outreach /routine trekking teams respectively.  The largest component of total costs associated with 
delivery by reproductive and child health trekking teams was the cost of administering IPTc.  This is 
because the trekking teams are skilled health care workers and so were paid substantially more for their 
time than the CHWs who received a monthly incentive payment of approximately US$11.10 (US$2010).  
Non-IPTc drugs (for example anti-malarials for treatment and paracetemol) contributed 22% of the total 
economic costs of delivery via CHWs compared to only 14% for the RCH trekking teams.  
 
None of the caretakers (n=390) interviewed in Basse during the study reported direct costs associated 
with receiving IPTc, such as travel costs, and only one caretaker reported a loss in earnings while accessing 
IPTc. 
 
For ethical reasons, no placebo group was included in the Basse study so it was not possible to compare 
the cost-effectiveness of these two strategies to current practice.  However, net cost-effectiveness was 
calculated by subtracting resources saved from the total programme compared to the relevant outcome 
measure. In terms of cost-effectiveness, this incremental analysis shows that the CHW strategy is both 
more effective and less costly than delivery of IPTc via RCH trekking team. Comparing delivery by CHWs  
to delivery by  RCH trekking team highlighted three positive incremental effects - a reduction in the 
number of malaria episodes averted, an improvement in the number of fully adherent children and an 
improvement in the number of children who received at least one dose. The CHW strategy was also less 
costly in both economic and financial terms resulting in an incremental saving of US$ 883 and US$ 1260, 
respectively.  This indicates that, in The Gambia, CHWs is the most appropriate delivery route for IPTc.   
 
Tivaouane, Senegal could be considered the most operational  of the studies reported so far  as it was left 
to the District Medical Officer to organise the delivery of IPTc and its associated costs using a lump sum of 
money provided by the research team. At this site, the a cost of receiving at least the first dose of each of 
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the 3 courses of SP+AQ was US$ 3.73 per child. The largest component of the cost of IPTc was the cost of 
drug administration by CHWs, this was driven by the amount of incentive they received.  
 
Modelling the Cost Effectiveness of IPTc  
Modelling was used to supplement the information available from the trials and to provide predictions 
where the trials could not, for practical reasons, provide estimates such as for many different settings or 
for severe outcomes.  A comprehensive individual-based model [13]which had been fitted to data from 
sites across sub-Saharan Africa and subsequently validated against trials of IPTc was used to simulate the 
epidemiological impact and cost-effectiveness of IPTi and IPTc [7].  Setting, drug or implementation 
characteristics were varied. Costs were based on a summary of all available costings of IPTc [3,4,5]. The 
approach adopted followed previous work on modelling the cost-effectiveness of malaria vaccines [14,15] 
and followed standard practices [16]. The primary outcomes were  the number of DALYs averted and cost 
per DALY averted. The predictions covered a period of ten years from the start of the IPTc programme.  
 
Simulations were run to investigate the effects of the different target age groups, seasonal or year-round 
delivery, transmission intensity, seasonality, treatment coverage and drug characteristics. IPTc was cost-
effective, defined using the threshold suggested by the World Bank of US2009 $223 per DALY, in nearly all 
the simulated scenarios.  The number of DALYs averted by IPTc was driven mainly by the predicted effect 
on deaths. Cost-effectiveness was predicted to decrease with low transmission, badly timed seasonal 
delivery in a seasonal setting, short-acting and more expensive drugs, high frequencies of drug resistance 
and high levels of treatment of malaria fevers.  The number of DALYs averted was predicted to decrease if 
a target five-year age-band for IPTc was shifted from children under 5 years into older ages, except at very 
low transmission intensities. 
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3. Financial costs of delivering IPTc to children under ten years 
of age at scale in Senegal 
 
 
Background 
In this section we present the recently calculated, and therefore as yet unpublished, financial costs of 
delivering IPTc at scale in Senegal. The aim of the Senegalese study is to evaluate the safety, cost 
effectiveness and public health impact of seasonal IPT in children with SP+AQ when delivered by district 
health staff. The study design is described in the paper on safety of IPTc [17]. In brief, the 54 rural health 
posts in four districts (Bambey, Mbour, Fatick and Niakhar) were randomized to start implementation of 
IPTc in 2008 (9 health posts), 2009 (18 health post), 2010 (18 health posts), or, pending interim analysis of 
effectiveness, in 2011 (9 health posts). In 2008, children aged 3-60 months at the time of the first round of 
treatment were included, in 2009 the age range was increased to include children up to the age of 120 
months. A census of the study area was carried out in March-May 2008. In August 2008, all households 
were revisited to give each mother/carer a card bearing an ID number for the household, for the 
mother/carer, and for each child in her care, with space for IPT, Vitamin A and mebendazole doses to be 
recorded. Health facilities were provided with blank forms to be issued to first-time mothers at their first 
contact with health staff after delivery. From September 2008, rounds of household visits were initiated 
to record changes in household occupancy.  
 
The population served by each health post (2008 estimates) ranges from 1,772 to 42,374 with a median of 
8,400. The number of children aged 0-120 months ranges from 592 to 16363 (median 2694), and the 
number of those aged 0-59 months ranges from 309 to 9020 (median 1420) per health post. Each health 
post is usually staffed by 4 people - a full-time nurse, an assistant (Agent Sante Communautaire), a 
community health worker responsible for taking payments, and a midwife or birth attendant. The study 
area also has 72 cases de sante (health huts), smaller facilities staffed part-time by one community health 
volunteer who has received a short period of training. Vitamin A is delivered to children aged 6 months to 
5 years twice per year (usually around June and December) by community health workers (CHWs, or 
‘relais’) who visit each household. Children aged 1-5 years are also treated with mebendazole during 
these visits. In Bambey district, from 2006-2009, azithromycin treatment was delivered to all age groups 
above 6 months except pregnant women, once per year during the period of  November to December for 
control of trachoma. About 59% of 12-23 month old children are fully vaccinated. In 2010, detailed data 
on costs of delivery of IPTc were collected in order to estimate the incremental financial and economic 
costs of implementing IPTc at scale.  All 46 health facilities that delivered IPTc in 2010 were included (45 
health posts and one mission health centre which contributed to IPT delivery).  
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Both financial and economic costs were collected as part of the study, however, this report presents only 
the incremental financial costs of implementing IPTc. The final report, which will be submitted for 
publication in a peer-reviewed journal, will include the full incremental economic costs of implementing 
IPTc. These financial costs are an indication of the additional funding that districts would need to 
implement IPTc in future in the same manner. The analysis of economic costs, which is in preparation, will 
assess the value of the additional resources used to implement IPTc, including those which did not incur a 
financial cost, such as the time required of the district health team, health post staff, and CHWs. The 
opportunity cost for households to participate in IPTc is being explored through qualitative work, but is 
expected to be low as IPTc is delivered door-to-door. 
 
 
Methods 
 
Delivery strategy 
A series of consultations were held with district health staff to identify the most appropriate method of 
delivery, the approach adopted was similar to that used for Vitamin A, using community health workers 
paid a daily rate to deliver house to house. Before the main study, a pilot study in three health posts in 
2006 and 2007, showed that high coverage could be achieved, and there was good compliance with both 
the IPT doses supervised by the CHW and the doses of amodiaquine taken unsupervised. In 2008 project 
staff provided training and supervision for IPT delivery, these inputs were gradually reduced and in 2010 
were primarily organised by the district health teams. Drugs for IPT were provided to the district health 
centre each month, which then organised distribution to health posts. Administration started on the same 
date in each health post, the 5 day period at the middle of each month was chosen taking into account 
public holidays, and other health activities of district staff. Training workshops for nurses and CHWs were 
organised by the district medical officers and community sensitization and local mobilisation were 
organised by the district communication officer. In September 2010, each health post was provided with a 
printed register for each village in their catchment area, listing eligible children. CHWs, who worked in 
pairs, were assigned by the nurse a circuit of villages to visit over a 5 day period in September, October 
and November, they visited house to house to administer the first dose of IPT each month, all children 
aged 3-120 months who were normally resident in the village were eligible, those not listed in the register 
being added to the list. Breakable dispersible AQ and SP tablets were used, mixed with water provide by 
the household, with dosage determined by age group. Successful treatment, refusal or vomitting was 
noted in the register and the date of treatment recorded on the mother's DSS card, and the mother was 
given amodiaquine tablets to give to the child on each of the next two days. At end of each day, the CHWs 
reported to the health post the number of children seen, drugs remaining, and checked the register for 
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any children who had been missed, and the nurse then issued CHWs with drugs for the next day. Health 
posts had supervisory visits each month during IPT administration from either the district public health 
officer, the district medical officer, or the project’s district supervisor. 
 
Head nurses had considerable autonomy in deciding how to manage IPTc administration at their health 
post. Some had experience of organising IPT in previous years - of the 46 health posts, 18 were 
administering IPTc for the first time, 19 were in their second year of administration, and 9 were in their 
third year of administration. In most cases, they trained CHWs over the course of several hours on the day 
before administration in September, but did not repeat this full training in October and November.   
 
Each head nurse received a lump sum payment to cover CHW incentives based on the estimated number 
of CHWs needed and the estimated number of days work it would take the CHWs to cover the IPTc target 
population of each health post.  Each head nurse was responsible for organising the hire of CHWs, the 
number of days they were hired for, and their payment. Some nurses chose to divide the lump sum by the 
number of CHWs aligned to their health post and pay CHWs a fixed amount as an incentive, while others 
paid on a daily rate.  Further analysis of how payment schemes impacted delivery is being conducted.  
 
This study takes a provider perspective. The focus is on costs of implementation at the district-level and 
below.  Costs incurred only at national level, such as those associated with meetings amongst national-
level representatives, are not included. Nearly all the costs of implementation from the district level and 
below were considered to be recurrent, meaning that they would have to be repeated for each year of 
implementation. The only capital costs (resources that last over a year) associated with IPTc 
implementation were those of the research team vehicles, which were used in a few instances to support 
the distribution of IPTc drugs and supervision. 
 
The costs of research activities were generally excluded from the analysis.  However, in two cases, costs 
associated with research activities were very likely to have contributed directly to the success of the 
administration and so they have been included and are described in detail.  While all costs of the 
demographic surveillance system (DSS) set up to support the trial were excluded, some of the DSS 
fieldworkers and supervisors provided supervisory support on the administration days in September and 
October and transported some of the drugs; the costs of their time and of drivers and vehicles for these 
implementation activities have, therefore, been included under supervision and supply chain, 
respectively.  In addition, health staff at post, district, and regional levels received incentives for 
participation in the research.  These incentives were paid over the 12 months of the year and were 
intended to support participation in research activities such as morbidity surveillance. While it is not 
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anticipated that such incentives would be paid if IPTc were implemented outside a study context, these 
incentives may have contributed to more assiduous implementation of IPTc, and so they are also 
presented as a separate cost category. 
 
Data collection  
Tools were developed to collect data on costs and resource use at four levels: the project, the district, the 
health post, and the CHW. The project-level budget tool captured data on the total quantity and unit costs 
of drugs and supplies purchased centrally, incentive payments, cash transfers to districts and prefectures 
for fuel costs, the number and cost of some of the meetings and training session,; resource use associated 
with the delivery of drugs and supplies, and the number of days’ supervision  and associated costs of DSS 
fieldworkers and supervisors.   
 
At the district, health post, and CHW levels, questionnaires were developed, introduced to all district 
medical officers, head nurses, and CHWs at the IPTc planning meetings before IPTc administration began, 
and refined to incorporate their feedback. Data were collected from all four districts and all 46 health 
posts following each round of administration in September, October, and November. District and health 
post questionnaires covered similar areas so that data could be triangulated: time spent and incentive 
payments received by staff for supervising administration of IPTc; resource use and costs of transport for 
the delivery of drugs and supplies and of personnel, meetings and training sessions, sensitization 
activities, and recording of all drugs and supplies received, bought, and used (or wasted) over the course 
of administration. Both questionnaires collected data on the number of years of experience of 
implementing IPTc for the facility and for the particular district medical officer or head nurse so as to 
explore determinants of resource use and efficiency. In addition, the health post questionnaire collected 
detailed data on the number and composition of CHW teams, the incentives paid to them, and the 
number of children who received treatment from each relais team. 
 
 
The CHW questionnaire was administered to a representative, systematic sample of CHWs each month. 
The CHW questionnaire collected basic demographic information, data on the CHW’s experience in 
administering IPTc, the number of days worked, training and per diems received that month, the type of 
transport used, who paid for it, and the cost, the villages covered on each day of administration, and any 
other costs associated with IPTc.  
 
 
Data analysis 
Coverage levels were estimated based on routinely collected activity data as well as a cross-sectional 
household survey conducted in December 2010.  
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Costs were summarized according to the categories presented in Table 2. These categories were 
established to ensure comparability with previous studies of IPTc [3,4] and to reflect the key IPTc cost 
centres. Costs are presented as the total incremental financial cost for administration in the 46 health 
posts in both the local currency, the West African Franc (XOF), and in United States Dollars (US$US$) 
based on the average 2010 exchange rate (1 US$US$ = 495 XOF). While previous papers have tended to 
focus on the cost per fully adherent child (i.e. per child receiving three doses of IPTc), this study presents 
the incremental financial cost of IPTc per course administered. Each course of IPTc protects a child from 
malaria for approximately one month. Thus, children who receive only one or two courses of IPTc derive 
important benefits, which would not be taken into account if only fully adherent children were 
considered.  Furthermore, given the highly mobile nature of populations both in the study area and in 
other areas where IPTc is likely to be of benefit, children may have missed doses because they were away 
from the area and, therefore either not exposed to malaria or potentially able to receive IPTc elsewhere if 
it was available more widely. Additional data on resource use and unit costs of key cost drivers are also 
presented.  
 
Future analyses will consider the economic costs of implementation and will disaggregate findings by such 
variables as the number of years of experience at the health post in delivering IPTc. 
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Table 2. Description of cost categories 
 
COST CATEGORY DESCRIPTION 
1. IPTc Drugs  
 This reflects the cost of sulphadoxine-pyrimethamine (SP) and amodiaquine (AQ) actually used 
or wasted during IPTc administration. Unit costs reflect the cost of the drugs themselves and the 
costs of importation to the Port of Dakar.    
2. Drug 
Transport/ 
Supply Chain 
This reflects the cost of transporting drugs from Dakar to the districts (via a local storage site) 
by the research team, and from the districts to the health posts by district and health post staff. 
When research team drivers were used, their daily wage rate has been included. 
3. Drug 
Administration 
(CHWs) 
This includes the cost of payments of per diems to and transport for CHWs to come to the health 
post, retrieve drugs and registers, administer drugs to children, and return to the health post to 
return their reports and remaining drugs on each day of the administration. Transport costs 
paid by the CHW and not reimbursed by the health facility have been excluded.  
4. Supervision 
This reflects the cost of incentive payments to a head nurse, assistant, and in some cases trainee 
at each health post; to each district health management team, region, and prefecture to 
supervise the implementation of IPTc and to manage any side effects or refusals; and the costs 
of any transport used for this supervision. The pro-rata costs of wages and transport for the 
demographic surveillance system (DSS) supervisors and fieldworkers have also been included for 
the days on which they helped districts to supervise the administration.    
5. Training of 
CHWs 
CHWs attended a single  day of training at their health post before administration in September. 
The payment of per diems, as well as the costs of any food or supplies provided or used during 
the training and any transport paid for by the health post and the district are included. The costs 
of the head nurse’s incentive payments are included under “supervision”. 
6. Training of 
head nurses 
 Head nurses travelled to their district health centre for a single day of training before 
administration in September. Costs include the per diems paid to the head nurses, the costs of 
their transport, and the costs of any food or supplies provided. The District Health Mangement 
Teams, who led the training, did not receive any per diems specifically for the training. 
7. Evaluation & 
planning 
meetings 
Prior to the training, head nurses attended one or more evaluation and planning meetings at 
their district during which they evaluated results of the IPTc implementation in 2009 and 
outlined plans and budgets for implementation of IPTc in 2010. Costs include per diems, 
transport, and any food or materials provided specifically for the meetings. Meetings were held 
for head nurses at district level and for district managers in Dakar and at one of the districts. 
8. Sensitisation  
Both districts and health posts arranged activities to promote awareness of IPTc within the 
community, such as travelling caravans, radio announcements, and community meetings. The 
costs of meetings with regional or local authorities are also included. 
9. Drugs for side 
effects 
Health posts were provided with a small stock of drugs and medical supplies with which to 
manage potential adverse events. The amount provided to health posts was costed regardless 
of the amount used, as these supplies would need to be provided again in future. In addition, 
head nurses were reimbursed the cost of treating children whose parents reported side effects, 
in cases where the head nurse used medications other than those provided. 
10. Supplies 
All supplies used in the administration were costed.  These included hats, t-shirts, and polo shirts 
with IPTc sensitization messages and the MoH logo; registers of children and other monitoring 
tools; phone cards, etc. provided to them. In addition, health posts also purchased some 
supplies themselves, such as pencils and erasers, to complement those provided by the district; 
these costs have also been included. 
11. Research 
participation 
incentives 
Regional medical officers, district medical officers, and head nurses all received quarterly 
incentive payments throughout the year to support research activities such as morbidity 
surveillance. The entire value of these payments over 12 months to the 3 regions, 4 districts, and 
45 health posts that implemented IPTc in 2010 are included, as they are likely to have 
contributed to more assiduous implementation of IPTc in September, October, and November. It 
is not expected that this level of incentive payment would be repeated outside a research 
context. 
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RESULTS 
 
The head nurse in each of the 46 health posts was interviewed after each round of IPT, completed 
questionnaires were also collected from 405 CHWs, reflecting 48% of the average of 822 CHWs who 
administered IPTc each month, and district level expenditures were collected from each district each 
month. A total of 471,282 documented courses of treatment were administered by CHWs working in 
pairs, delivering IPT to on average 90 children per day (Table 3). Health posts employed from 4 to 68 
CHWs and delivery each month took from 2 to 5 days (Table 4). High coverage was achieved with about 
90% of eligible children  treated each month. In total, it cost $233,714 to administer IPTc to a population 
of 175,000 children under 10 years of age in 4 districts of Senegal over one malaria season, achieving an 
average monthly coverage of 90% (Table 3) at a cost of $0.50 per course (Table 5).  
 
Table 3. Estimated coverage and total number of course administered 
  TOTAL 
District 
Mbour Bambey Fatick Niakhar 
Estimated 
coverage 
Sept 88% 78% 94% 80% 87% 
Oct 90% 80% 96% 79% 91% 
Nov 91% 79% 98% 79% 95% 
Courses 
administered 
Sept 154,013 34,401 74,047 22551 23,014 
Oct 157,602 35,310 76,018 22219 24,055 
Nov 159,667 35,000 77,292 22405 24,970 
Total 471,282 104,711 227,357 67175 72,039 
* Coverage estimated as the number of courses delivered divided by the estimated population eligible to receive IPT, from the DSS.  
 
The main cost drivers in this study were the costs of the drugs (representing 24% of non-research costs, 
Table 5) and the incentives paid to CHWs (44%). Incentives paid to nurses and district staff may have 
contributed to the success of delivery and such incentives are not normally provided for programme, 
although these form a relatively small proportion of total costs.  
 
The incentives paid to CHWs in this project (Table 6) were similar to those paid by the National Malaria 
Control Programme for community health activities, somewhat less than is paid by some NGOs, but 
somewhat higher than is paid for delivery of Vitamin A. Vitamin A delivery in Senegal is organised by the 
La Division de l’Alimentation, de la Nutrition et de la Survie de l’Enfant (DANSE), each district is provided 
with Vitamin A capsules and a budget of 1,200,000 CFA for each round of delivery. To compare these 
costs with our costs, the economic costs of district logistics, transport etc used in Vitamin A campaigns will 
need to be taken into account.  
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Table 4. Resources involved in IPTc delivery 
 Number / 
mean 
Health post range 
Low High 
Health 
structures 
Regions 3   
Districts 4   
Health posts1 46   
Health 
workers 
Head nurses 46   
Assistant nurses2 46   
CHWs administering IPTc each month 
(mean)  
831   
CHWs administering IPTc each month 
per health post (mean) 
18.1 4.0 68.0 
Number of days worked on IPTc per 
month per CHW (mean) 
4.2 2.3 5.0 
Outputs per 
structure/ 
worker 
IPTc courses administered each month 
per health post (mean) 
3,456 502 16,720 
IPTc courses administered each month 
per CHW (mean) 
189.2 104.5 268.9 
IPTc courses administered each month 
per CHW per day (mean) 
45.3 31.5 89.0 
145 government health posts were randomized to receive IPTc; an additional Catholic mission 
health post within the catchment area of one of the government posts also participated and is 
included here. 
2All head nurses have an assistant, but some assistants are community health agents while 
others are members of the health service. 
 
 
High coverage was obtained in our study area, the coverage estimates may somewhat overestimate the 
true coverage as they are based on estimates of the eligible population from the demographic 
surveillance system. Children present in the household on the day of IPT delivery who were aged between 
3 and 120 months, who were not in the DSS list, were also offered IPT if they were normally resident in 
the village. However the estimates are consistent with survey estimates of coverage in 2009, based on 
recorded doses on the DSS card and parental recall. The survey also showed that a high proportion of 
children received three monthly doses (2009 data: 89.6% had three courses, 3.2% two courses, 1.6% one 
course, and 5.6% received no IPT). 
 
Costs of publicity campaigns run each month just before each round of IPT were included in these 
costings, these campaigns were important in ensuring good uptake.   
 
The fact that listings of children were provided from the DSS may have helped to identify eligible children. 
The costs of the DSS have not been included, although the costs of printing the materials for them to keep 
track have been printed. On the other hand, completing the registers took additional time. In Vitamin A 
campaigns there is a tally of total doses delivered but no individual recording of children treated. In our 
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study IPTc doses were recorded in a register and on the mother’s card, however accurate recording of 
doses received is essential if impact is to be monitored for example using case control studies to measure 
efficacy of the intervention or rebound effects, and for adverse event monitoring.  
 
Table 5. Financial costs of IPTc by cost category 
 
 
Total  Costs Cost per course Cost profile 
(XOF) (US$US$) (XOF) (US$US$) 
including 
research 
incentives (%) 
excluding 
research 
incentives (%) 
TOTAL 115 719 136 $233 714 245,54 $0.50 100% 100% 
Cost IPTc Drugs (SP+AQ) 21,991,407 $44,415 46.66 $0.09 19% 24% 
Drug Transport/Supply Chain 454,814 $919 0.97 $0.00 0% 1% 
Drug Administration (CHWs) 39 808 879 $80,401 84.47 $0.17 34% 44% 
Supervision 13 972 312 $28,219 29.65 $0.06 12% 15% 
Training of CHWs 3,554,337 $7,179 7.54 $0.02 3% 4% 
Training of ICPs 951,241 $1,921 2.02 $0.00 1% 1% 
Meetings - evaluation & planning 1,170,500 $2,364 2.48 $0.01 1% 1% 
Sensitisation  770,100 $1,555 1.63 $0.00 1% 1% 
Drugs for side effects 604,025 $1,220 1.28 $0.00 1% 1% 
Supplies 7 346 521 $14,837 15.59 $0.03 6% 8% 
Research participation incentives 25,095,000 $50,683 53.25 $0.11 22% x 
 
 
 
 
In most of the clinical trials of IPTc the intervention has been administered to children up to 5 years of 
age. In this study the inclusion of children up to ten years of age may allow for significant economies of 
scope to be gained in administering IPTc to a greater proportion of the children within each household 
visited. Coverage amongst children over 5years old was similar to that achieved in under 5’s (data not 
shown). During the year community health workers may visit households a number of times for Vitamin A 
and mebendazole delivery, bednet distribution, mass vaccination campaigns and other programmes, 
opportunities therefore exist for further economies of scope by combining IPTc with delivery of other 
interventions.  
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Table 6. Unit costs of key cost drivers 
 Article Unit costs Total quantity 
XOF US$US$ 
IPTc Drugs 
Sulphadoxine-pyremethamine (SP) 11 0.02 515,126 Tablets 
Amodiaquine (AQ) 11 0.02 1,514,054 Tablets 
Incentive 
payments for IPTc 
administration 
CHW daily per diem (mean) 3,755 7.59  CHW-days 
CHW per diems received for one month of 
IPTc administration (mean) 
15,723 31.76  CHWs 
Head nurse IPTc incentive payments (total 
per year per nurse) 1 
120,000 242.42 46 Nurses 
Head nurse IPTc incentive payments (as % 
of mean annual net salary) 
4.2%   46 Nurses 
Assistant nurse IPTc incentive payments 
(total per year per nurse) 
60,000 121.21 46 Assistant 
nurses 
Assistant nurse IPTc incentive payments 
(as % of mean annual net salary) 
25.0%   46 Assistant 
nurses 
Funds provided 
for fuel costs for 
supervision 
District payments (total per year per 
district) 
289,800 585 4 Districts 
Prefecture payments (total per year per 
prefecture) 
193,200 390 4 Prefectures 
Research 
participation 
incentives 
Head nurse (Total per year per nurse) 200,000 404 45 Nurses 
District (Total per year per district) 2,820,000 5697 4 Districts 
Region (Total per year per region) 900,000 1818 3 Regions 
1 
Incentives received over the 4 months of IPTc delivery
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4. General discussion and conclusions 
 
 
Across the studies, supervision, training and remuneration of CHWs and ensuring IPTc drug delivery were 
identified as the main cost components and key determinants to the success of the delivery strategy of 
IPTc.  There is scope for the costs associated with supervision and training to be reduced if IPTc is 
integrated into existing routine activities.  Alternatively, in settings where supervision and training of 
CHWs is weak, IPTc may offer an opportunity to strengthen both these important aspects of service 
delivery which will offer benefits beyond reducing malaria morbidity and mortality.   
 
 
How does IPTc compare to other malaria intervention costs? 
i)Costs of IPTi  
Two types of unit costs for IPTc have been presented in this report.  The first is the ‘cost per course’ which 
reflects total costs divided by total courses delivered.  In Senegal, the recently calculated financial cost per 
IPTc course is US$0.50.  Across all studies, the financial costs per course range from US$0.24 to US$3.44 
and the economic costs per course from US$0.31 to US$3.44.  The second option for assessing the unit 
cost of IPTc is ‘the cost of delivering at least the first one dose of each course of IPTc’ to take into account 
the number of children who fully engaged with the intervention as intended.   
 
At between US$8.30 and US$15.03 the annual cost of delivering IPTc under trial conditions was higher in 
Hohoe, Ghana than that of other interventions designed to protect children against malaria. However, the 
highest costs in this study relate to a regimen which involved the administration of up to 6 courses of IPTc 
as opposed to the three courses used in most other studies. When unit costs were scaled up to a district 
wide level, costs of delivery in this region of Ghana fell to between US$1.74 and US$4.20 per child, 
comparable to the findings obtained in a larger study conducted in Basse, Gambia where the cost per 
child who received at least the first dose of each of  3 courses of IPTc  was US$1.66 when this was 
administered via CHWs and $3.53 when it was given through  outreach services. These costs are within 
the range of the costs associated with delivering existing malaria control interventions.  For example, the 
costs per year of protection in US$2010 associated with insecticide treated nets (ITNs) are reported to be 
US$1.48-4.05[24], US$3.67-6.14 for indoor residual spraying (IRS)[25], US$0.76 for intermittent treatment 
of malaria (IPT) in infants using three doses of SP [26],  US$2.05 for IPT in school children [27] and  
US$2.73  for delivery of   2 doses of IPT to pregnant woman (using SP) via community care and US$2.42 
when delivered  via health centres[28].  
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ii) Cost-effectiveness of IPTi  
Comparisons of ICERs across studies should be interpreted with caution due to methodological 
differences (e.g. some take account of resource savings and some do not, some take a societal 
perspective while others take a provider perspective) and cultural and epidemiological profiles may  
differ.  With this in mind, based on intervention costs alone, the cost of averting an episode of malaria in 
Hohoe with IPTc is high (US$67.77) compared to other malaria interventions which report the cost per 
malaria episode averted among under fives of between US$3.71 for ITNs [18] and US$24.00 to US$26.58 
for IRS [19].  Figure 3,  taken from a summary report recently compiled for the Roll Back Malaria 
Partnership reviews the available data on the costs and cost effectiveness of various malaria strategies 
[20].  While caution should be taken when interpreting the data as there was considerable variation in the 
definition of a case of malaria across the 57 cost and 24 cost effectiveness studies included in the review, 
the costs of averting a case of malaria via IPTc are  comparable to other malaria interventions.  In 
addition, IPTc was predicted to fall within the bounds of being cost-effective (<$223 per DALY) for nearly 
all of the simulated scenarios[7]. The differences between the predictions and the trial estimates are likely 
to be due to the inclusion of deaths and severe episodes, the inclusion of all episodes as opposed to those 
detected by passive case detection alone, and careful exclusion of costs related specifically to research.  
 
The calculations considered above are based on the findings of administration of IPTc under trial 
conditions for one year although it is proposed that IPTc would be given for the first few years of life.  
Provided that the same level of protection is achieved each year that IPTc is given, the cost effectiveness 
ratios achieved in the first year should be repeated in subsequent years, in fact CERs could improve if 
protection remained constant and costs reduced as the intervention was delivered more efficiently over 
time.  Studies undertaken so far have shown little evidence of a rebound in the incidence of malaria in the 
year after IPTc was given [2]. However, previous studies in which children were protected against malaria 
by seasonal chemoprophylaxis indicated that there was a significant increase in clinical attacks of malaria 
in the year after the intervention stopped in children who had received chemoprophylaxis from the age of 
3 months to 5 years [21]. If several years of IPT have a similar effect, this would need to be taken into 
account in assessing the overall cost effectiveness of the intervention.       
 
Supply side –the impact of IPTc on the health system 
IPTc studies have used various delivery systems to achieve high levels of IPTc coverage.   There is scope to 
deliver IPTc using one delivery strategy or a combination of two or more different strategies depending on 
the setting. However, evidence gained to date suggests that, in most settings, community health workers 
are likely to be the most effective way of delivering IPTc as  they have achieved higher levels of coverage 
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and lower costs than IPTc delivered  by staff of  outpatient departments  and trekking/outreach clinics 
[4,5,22].  
 
Figure 3:  Cost per malaria case averted broken down by prevention strategy 
 
Figure based on [20]; ITN: Insecticide treated nets; IRS: Indoor residual household spraying; IPTsc: IPT in 
school children 
 
Central to the success of IPTc is the sustainability of the community health worker network. Increasing 
attention is being given to the role of CHWs in public health programmes [23,24].  Although we refer to 
CHWs throughout this report, we recognise that there is a wide spectrum of lay health workers and 
volunteers with varying roles and responsibilities contributing to health and other community 
programmes.  We use the term CHW as an umbrella for all community based health agents and recognise 
that the  potential role of different categories of CHWs in IPTc delivery is an area for future research.  The 
challenges of scaling up and sustaining community–based interventions are varied and, if IPTc is to be 
launched on a large scale, those responsible for its implementation could learn from some of the 
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constraints to scaling up identified by other community based studies that have successfully scaled up 
from small scale experiments to districts [25,26]. Challenges are likely to include managing the time lag 
between the onset of planning and the  launch of services, discrepancies between the knowledge about 
the intervention held by the different stakeholders and their perceived roles and responsibilities and the 
need for additional resources at the primary health care level, if staff, materials and supplies are already 
severely constrained. While these challenges are to be expected, findings from both studies in Senegal 
suggest that they can be overcome if there is absorption capacity and genuine commitment at all tiers of 
the health system [6]. 
 
 
The role of incentives 
As well as political will and commitment among health care providers, the issue of remunerations, be they 
financial or non-financial, is crucial to the sustainability of IPTc.  The recognition that  CHWs need to be 
compensated was central to the success of the studies considered in this report and an important factor 
in other successful community health interventions[27]. In the studies costed, CHW were paid as an 
incentive between US$ 11 and 32 per month (US$ 2010) to deliver IPTc, see Table 7.  Health staff were 
also paid incentives to help motivate them and support the delivery of IPTc. The role of incentives was 
most pronounced in both studies based in Senegal. For example in Tivaouane, the district-led 
implementation site, where incentives comprised approximately 10% of total intervention costs. At  
$31.76 per month the incentives given to CHW in the 4 district study is high, but the daily rate is 
consistent with what CHWs receive for many other health activities in Senegal, although somewhat higher 
than is paid  in  Vitamin A campaigns. Across the studies, the level of incentives was decided by the 
research teams, health professionals and by assessing the payments CHW received from existing 
campaigns.  If and how these incentives could/should be sustained needs to be explored further. It is 
important to consider carefully what level the incentive should be set at to avoid wage inflation and 
market distortions, as setting the incentive too high or low will impact other CHW programmes and have 
implications on the equilibrium market price of CHW services.   
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Table 7: Monthly Incentives paid by studies to individual health providers for IPTc Delivery* 
(US$ 2010) 
  CHW Nurses DHMT Driver 
Basse,  
Gambia 
CHW 11.10 no incentives no incentives 13.88 
Outreach no incentives 25.98 no incentives 13.88 
Jasikan,  
Ghana 
CHW 10.60  53.65 (Senior) no incentives 16.10 
Outreach no incentives 53.65 (Senior) 
10.60 (Dispensers) 
no incentives 16.10 
OPD no incentives 53.65 (Senior) 
10.60 (Dispensers) 
no incentives 16.10 
Hohoe,  
Ghana 
 12.00 no incentives no incentives no incentives 
Tivaouane, 
Senegal 
CHW 20.98 96.21 149.86 (DMO) 
99.91 (Deputy DMO) 
14.34 
4 Districts,  
Senegal 
CHW 31.76 60.61 (Head) 
30.30 (Assistant) 
157.50 (DMO) 
105.00 (Deputy DMO) 
73.50 (Supervisor) 
no incentives 
Average  17.29 42.09 117.15 14.77 
Min  10.60 25.98  73.50 13.88 
Max  31.76 96.21 157.50 16.1 
* Incentives for the research component of the studies are not included 
DHMT: District Health Medical Team 
DMO: District Medical Officer  
 
 
Demand Side –household engagement 
This report has focused on the costs and potential benefits of IPTc to the health system and the providers 
who are responsible for supplying health care, with limited discussion on the costs and benefits of IPTc to 
households.  In the Gambia, the costs of accessing IPTc (directly and indirectly in terms of time lost) were 
calculated and only one caregiver reported a loss of income. In all studies there has been a willingness to 
give time to receive IPTc and, if IPTc is delivered in the community the cost of accessing IPTc  appear to be 
negligible.  Even in the trials in Mali and Burkina Faso where caretakers were asked to visit a health facility 
on 3 consecutive days with the study children, those who had initially dropped out or felt it was too much 
of an onerous task, subsequently wished to join the programme  after they had  witnessed firsthand the 
benefits the IPTc trial was having on the children in their communities[28].  This enthusiasm of caretakers 
to enrol in a study that averts malaria is totally rational given the heavy direct and indirect costs a visit to 
a hospital can have on a household when a child suffers an episode of malaria. 
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To conclude, in this report we present the costs and cost-effective of IPTc using three different drug 
regimens and various delivery strategies.  While the cost of the intervention is marginally higher than that 
of delivering other prevention strategies, possibilities exist for reducing the costs of IPTc by scaling  up 
delivery to the district level and by incorporat delivery of IPTc  with the delivery of other interventions 
such as the distribution of Vitamin A or HMM. Supervision, training and remuneration of CHWs and  IPTc 
drug delivery have been identified as the main cost components and key determinants to the success of 
the delivery strategy.   
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Annex 1: Studies with a Socio-Economic Component 
Adapted from [2] 
  
 
Kweku et al (2008)  
[29] 
Bojang et al, (2011) 
[4] 
Kweku et al (2009) 
[30] 
Cisse et al [6] Dicko et al, (2011) [11] Konaté et al, 
(2011) [12] 
Senegal 4 
Districts 
Ch
ar
ac
te
ris
tic
s 
of
 s
tu
dy
 a
re
a 
Location Hohoe, Ghana Basse, The Gambia Jasikan, Ghana Tivaouane, Senegal Siby,  Djoliba and 
Ouelessebougou, Kati 
administrative region,  
Mali 
Toeghin, Niou, 
Laye and Sao, 
Boussé District  
Burkina Faso 
Mbour, Bambey, 
Fatick districts, 
Senegal 
Rainy season Major Apr-Jul, minor 
Sept-Nov  
July – Nov Apr-Nov (peaks in 
May-Jul. and Sept.-
Oct.) 
Jul. to beginning of 
Oct 
Jun-Oct Jun-Oct May/Jun - Sept 
EIR / year 65B  1 - 50 per year 65 10 7 – 37 7 – 37 173 
Bednet usage 20% slept under (any)  
bednet / II% slept 
under ITN 
50% / 62%  slept 
under intact or 
impregnated 
bednet 
Bednet usage 19% / 
ITN usage 14% 
Bednet usage 28% / 
ITN usage 13% 
>99% ITN usage >99% ITN usage 93% ITN usage 
St
ud
y 
Ch
ar
ac
te
ris
tic
s 
Recruitment Year 2005 2006 2006 2006 2008 2008 2008-2-10 
Design Individual 
randomisation 
Cluster 
randomisation 
Cluster 
randomisation 
 
Cluster 
randomisation 
 
Multi-centre, individual randomisation, 
double blind 
Large-scale 
implementation 
Control arm Placebo Non – Controlled Non – Controlled Non – Controlled Placebo + ITN Non – Controlled 
For Controlled No. 
of children 
randomised, control 
/ active arm or for 
non-controlled  No. 
of children 
randomised / 
enrolled 
650 / 1801  12,326 962  5630 1508 / 1509 1505 / 1509 184,795 
Age range enrolled 3-59 months 6-59 months 3-59 months 3-59 months 3–59 months 3-59 months 
(<120 mths in 
2009&2010) 
Drug SP bimonthly 
AS+AQ bimonthly 
AS+AQ monthly 
SP+AQ monthly SP+AQ 
(May/Jun./Sept./Oct) 
SP+AQ monthly SP+AQ monthly SP+AQ monthly 
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 Kweku et al (2008)  
[29] 
Bojang et al, 
(2011) [4] 
Kweku et al (2009) 
[30] 
Cisse et al [6] Dicko et al, 
(2011) [11] 
Konaté et 
al, (2011) 
[12] 
Senegal 4 Districts 
St
ud
y 
Ch
ar
ac
te
ris
tic
s 
Dosing By age: 
AQ/AS 
(150mg/50mg) 
SP (500/25mg)    
3-5 months ¼ tab,  
6-11 months ½ tab,  
12-23 months ¾ tab 
≥24 months 1 tab 
By weight: 
SP 25mg S / 1.25 
mg P per kg 
 
AQ 25mg/kg over 
3 days  
(10mg/kg D1, 10 
mg/kg D2, 5mg/kg 
D3) 
By age: 
 
SP (500mg/25mg) 
AQ (150mg) 
 
3-5 months      1/4 
tab     
6-11 months    1/2 
tab     
12-23 months  3/4 
tab     
≥ 24 months    1 tab     
By age: 
 
SP (500mg/25mg) 
AQ (150mg) 
 
<24 months  1/2 
tab  
≥24 months  1 tab   
By weight: 
SP (25mg/kg / 1.25 mg/kg) 
 
AQ (10mg/kg daily for 3 days) 
 
By age: 
 
SP (500mg/25mg) 
AQ (153mg) 
 
3-23 months  1/2 tab     
24-71 months  1 tab     
72-120 months  1.5 tab     
 
Delivery Mechanism 
CHW  
 
  
CHW or 
Reproductive and 
Child Health (RCH) 
trekking team 
Health facility (OPD), 
EPI outreach  or CHW 
CHW Health facility CHW 
Supervision of doses  Directly observed 
treatment for 3 days 
 
Day 1 directly 
observed.    Day 2 
and 3 doses 
unsupervised 
Day 1 directly 
observed.    Day 2 
and 3 doses 
unsupervised 
Day 1 directly 
observed.    Day 2 
and 3 doses 
unsupervised 
Directly observed for 3 days Day 1 directly 
observed.    Day 2 and 
3 doses unsupervised 
So
ci
o-
Ec
on
om
ic
 S
tu
dy
 C
ha
ra
ct
er
is
tic
s 
Type of Socio-Economic 
Analysis 
Cost effectiveness of 
trial and modeled for 
district 
Incremental Cost 
effectiveness 
Costing Costing Qualitative study on 
introduction and potential for 
diffusion of IPTc  
Costing 
Costing Perspective Societal  
 
 
 
Provider Provider Provider  Provider 
Publication showing results Conteh et al 2010 [3] Bojang et al, 
(2011)  [4] 
Patouillard E, (in 
preparation) [5] 
Cisse et al (in 
preparation) [6] 
Pitt et al [28] In preparation 
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